1989 Volume 17 Issue 4 Pages 571-577
We investigated the effects of administrating Trapidil (300mg/day) for one year on the development of diabetic macro- and microangiopathies.
Although we found no statistical significance, the Trapidil-treated diabetics had less increases in Pulse Wave Velocity and less worsening of existing diabetic retinopathy compared to the control group of diabetics. The prevalence of increasing proteinuria was significantly lower in Trapidil-treated diabetics than in control diabetics. Control of diabetes did not deteriorate with Trapidil administration.
Thus, it was speculated that antiplatelet therapy has the potential to suppress the development of diabetic microangiopathy in addition to macroangiopathy.
